PhytoTech Therapeutics, Ltd. Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Sydney Australia (2014)
Status: Acquired by Harvest One Cannabis Inc. (2018)

Organization Overview

First Clinical Trial
2015
NCT03201835
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PhytoTech Therapeutics, Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (2 trials)

ptl201 (1 trial)

Drugs in Phase 1 Trials (1)

tetrahydrocannabinol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug Resistant Epilepsy (Phase 2)

Epilepsy (Phase 2)

Multiple Sclerosis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3